Coronary Physiology in STEMI patients today: Why? When? How?
Published: 08 April 2022
13m 2sPart 1 | Session 1 Introduction and Clinical Evidence Ziad A Ali, Joost Daemen, Zsolt Piroth
10m 42sPart 1 | Session 2 Limitations Joost Daemen
11m 8sPart 1 | Session 3 Practical Solutions
Physiology in STEMI patients is a controversial hot topic in interventional cardiology: it has been first demonstrated to enhance the benefits of full revascularization vs PCI only in the culprit lesion; then its effectiveness has been mitigated by clinical outcomes not showing any differences versus angiography-guided complete revascularization.
Join a panel of international expert in the discussion about a topic that is still controversial and may impact a large number of STEMI patients undergoing PCI.
Clinical evidence and cases from the real world will be the two key subjects debated during the breakout session at TIO 2022.
Key Learning Objectives
- To understand the current position of Key Opinion Leaders on physiology in STEMI patients
- To actively participate to the debate over the options offered in the cathlab to support physiology guided complete revascularization in STEMI patients
- To review the literature and defining the key clinical settings where physiology should play a role in the decision making
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Coronary Physiology in STEMI Patients Today: Why? When? How?
Coronary Physiology in Diffuse Disease
Ziad A Ali
Dr Ali is a board-certified cardiologist specialising in interventional and structural cardiology at St Francis Hospital and Heart Center in Roslyn, New York.
Ziad is an internationally renowned expert in complex high-risk indicated percutaneous coronary interventions (CHIP) including the treatment of chronic total occlusions (CTO) where the arteries in the heart become completely blocked.
Ziad specialises in the management of cardiovascular disease in patients with pre-existing kidney disease.
Dr Joost Daemen, MD, PhD obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Joost is actively involved in several drug-eluting stent trials and is Principal Investigator of 4 trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Joost is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.